Citizens Jmp Issues Positive Forecast for Celcuity (NASDAQ:CELC) Stock Price

Celcuity (NASDAQ:CELC) had its price target lifted by Citizens Jmp from $160.00 to $177.00 in a research note published on Wednesday,Benzinga reports. The firm currently has a market outperform rating on the stock.

Several other research analysts have also weighed in on CELC. Stifel Nicolaus set a $150.00 target price on shares of Celcuity in a research note on Monday, May 4th. Leerink Partners set a $155.00 price target on shares of Celcuity in a research note on Tuesday, June 2nd. Weiss Ratings upgraded shares of Celcuity from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, June 4th. Guggenheim reaffirmed a “buy” rating on shares of Celcuity in a research report on Wednesday, June 3rd. Finally, Citigroup reiterated an “outperform” rating on shares of Celcuity in a report on Wednesday. Eleven analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Celcuity presently has an average rating of “Moderate Buy” and an average target price of $155.18.

Celcuity Price Performance

NASDAQ:CELC opened at $91.51 on Wednesday. Celcuity has a 52 week low of $13.47 and a 52 week high of $151.02. The stock’s fifty day moving average is $109.87 and its two-hundred day moving average is $111.05. The company has a market capitalization of $4.46 billion, a P/E ratio of -23.46 and a beta of 0.16. The company has a quick ratio of 12.31, a current ratio of 12.31 and a debt-to-equity ratio of 6.04.

Celcuity (NASDAQ:CELC) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.97) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.10. Equities analysts expect that Celcuity will post -3.69 EPS for the current year.

Insider Activity at Celcuity

In other news, Director David Dalvey sold 25,000 shares of the stock in a transaction on Monday, May 4th. The stock was sold at an average price of $140.68, for a total value of $3,517,000.00. Following the sale, the director directly owned 65,000 shares in the company, valued at approximately $9,144,200. This trade represents a 27.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard E. Buller sold 9,000 shares of Celcuity stock in a transaction on Monday, May 4th. The shares were sold at an average price of $140.46, for a total value of $1,264,140.00. Following the completion of the transaction, the director owned 6,760 shares of the company’s stock, valued at approximately $949,509.60. This trade represents a 57.11% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.33% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Celcuity

A number of institutional investors and hedge funds have recently made changes to their positions in CELC. PNC Financial Services Group Inc. grew its position in Celcuity by 20.1% during the first quarter. PNC Financial Services Group Inc. now owns 514 shares of the company’s stock worth $59,000 after buying an additional 86 shares during the period. Ogorek Anthony Joseph NY ADV grew its holdings in shares of Celcuity by 19.7% in the 4th quarter. Ogorek Anthony Joseph NY ADV now owns 662 shares of the company’s stock worth $66,000 after acquiring an additional 109 shares during the period. US Bancorp DE increased its stake in Celcuity by 25.4% in the 3rd quarter. US Bancorp DE now owns 706 shares of the company’s stock valued at $35,000 after purchasing an additional 143 shares in the last quarter. Intech Investment Management LLC raised its holdings in Celcuity by 1.4% during the fourth quarter. Intech Investment Management LLC now owns 12,983 shares of the company’s stock worth $1,295,000 after purchasing an additional 183 shares during the last quarter. Finally, Aristides Capital LLC raised its holdings in Celcuity by 2.0% during the fourth quarter. Aristides Capital LLC now owns 15,303 shares of the company’s stock worth $1,526,000 after purchasing an additional 303 shares during the last quarter. 63.33% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Celcuity

Here are the key news stories impacting Celcuity this week:

• Positive Sentiment: Celcuity won FDA approval for REVTORPYK, its first U.S. approved drug and a potential new breast-cancer therapy with blockbuster potential. Article: Celcuity Announces FDA Approval of REVTORPYK
• Positive Sentiment: Citizens JMP raised its price target on Celcuity to $177 from $160 and kept an outperform rating, signaling confidence in the company’s upside after the approval. Article: Celcuity price target raised by Citizens JMP
• Neutral Sentiment: Management discussed FDA approval and commercial launch plans, but investors are still waiting for clearer details on timing, adoption, and early market reception. Article: Celcuity FDA approval and launch plans transcript
• Negative Sentiment: Reuters reported the stock fell in premarket trading because the drug’s commercial launch is delayed and tolerability concerns are overshadowing the approval news. Article: Celcuity shares fall as delayed launch eclipses FDA approval
• Negative Sentiment: MarketWatch highlighted that timeline questions around the breast-cancer treatment are weighing on sentiment, suggesting investors are focusing more on execution risk than the regulatory milestone. Article: Celcuity shares down, FDA approval outweighed by timeline questions

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.